Gossamer Bio Net Worth
Gossamer Bio Net Worth Breakdown | GOSS |
Gossamer Bio Net Worth Analysis
Gossamer Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Gossamer Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Gossamer Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Gossamer Bio's net worth analysis. One common approach is to calculate Gossamer Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Gossamer Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Gossamer Bio's net worth. This approach calculates the present value of Gossamer Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Gossamer Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Gossamer Bio's net worth. This involves comparing Gossamer Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Gossamer Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Gossamer Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gossamer Bio's net worth research are outlined below:
| Gossamer Bio generated a negative expected return over the last 90 days | |
| Gossamer Bio has some characteristics of a very speculative penny stock | |
| Gossamer Bio has high historical volatility and very poor performance | |
| Gossamer Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (179.82 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Gossamer Bio currently holds about 304.38 M in cash with (159.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gossamer Bio has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: FMR LLCs Strategic Acquisition of Gossamer Bio Inc Shares |
Gossamer Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gossamer Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gossamer Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Gossamer Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gossamer Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gossamer Bio backward and forwards among themselves. Gossamer Bio's institutional investor refers to the entity that pools money to purchase Gossamer Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2024-06-30 | 5.5 M | Alyeska Investment Group, L.p. | 2024-06-30 | 5.5 M | Eversept Partners, Llc | 2024-06-30 | 5.5 M | Hillhouse Capital Advisors, Ltd. | 2024-06-30 | 5 M | Citadel Advisors Llc | 2024-06-30 | 4.1 M | Opaleye Management Inc | 2024-06-30 | 3.9 M | Deutsche Bank Ag | 2024-06-30 | 3.8 M | Junked Platinum Investment Management Ltd | 2024-06-30 | 3.5 M | Ci Private Wealth Llc | 2024-06-30 | 3.4 M | Nea Management Company, Llc | 2024-06-30 | 18.1 M | Artal Group S A | 2024-06-30 | 13.3 M |
Follow Gossamer Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 184.82 M.Market Cap |
|
Project Gossamer Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.71) | (0.67) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (2.86) | (2.72) |
When accessing Gossamer Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Gossamer Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gossamer Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Gossamer Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gossamer Bio. Check Gossamer Bio's Beneish M Score to see the likelihood of Gossamer Bio's management manipulating its earnings.
Evaluate Gossamer Bio's management efficiency
Gossamer Bio has return on total asset (ROA) of (0.1124) % which means that it has lost $0.1124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9026) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to gain to -0.67 in 2024. At this time, Gossamer Bio's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 923.7 K in 2024, whereas Total Assets are likely to drop slightly above 293.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.41 | 0.39 | |
| Tangible Book Value Per Share | 0.41 | 0.39 | |
| Enterprise Value Over EBITDA | (1.86) | (1.95) | |
| Price Book Value Ratio | 2.22 | 2.33 | |
| Enterprise Value Multiple | (1.86) | (1.95) | |
| Price Fair Value | 2.22 | 2.33 | |
| Enterprise Value | 319.6 M | 613.3 M |
Leadership at Gossamer Bio emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 0.4257 | Revenue 105.3 M | Revenue Per Share 0.466 | Return On Equity (0.90) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gossamer Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gossamer Bio time-series forecasting models is one of many Gossamer Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gossamer Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Gossamer Bio Earnings per Share Projection vs Actual
Gossamer Bio Corporate Management
| Colin Rowlings | Senior CMC | Profile | |
| Robert Smith | Chief Officer | Profile | |
| Matt Cravets | Senior Biometrics | Profile | |
| Jeff Boerneke | General Secretary | Profile | |
| Richard MD | Chief Officer | Profile | |
| Mario Orlando | Senior Planning | Profile |
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.